Vaccine hesitancy in COVID-19 times. An update from Italy before flu season starts.
Betacoronavirus
COVID-19
Comorbidity
Coronavirus Infections
/ epidemiology
Global Health
Health Personnel
Humans
Influenza Vaccines
/ pharmacology
Influenza, Human
/ epidemiology
Alphainfluenzavirus
/ immunology
Pandemics
/ prevention & control
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Vaccination
/ methods
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
07 09 2020
07 09 2020
Historique:
received:
27
08
2020
accepted:
27
08
2020
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
23
9
2020
Statut:
epublish
Résumé
The COVID-19 pandemic and response caused a worrying decline in vaccine uptake around the world. In Italy, the immunization coverage targets set in the 2017-19 National Immunization Prevention Plan (PNPV) have been met only partially. The current public health emergency is likely to have negatively impacted on immunization , with the risk of re-occurrence of Vaccine-Preventable Diseases (VPDs) outbreaks. As flu season approaches, both National Health Institutions and the scientific community in Italy have taken action. Well in advance as compared to previous years, the Ministry of Health released the Circular to launch the 2020-2021 influenza immunization campaign which this year is longer (starting on October 2020) and extends flu vaccine recommendations to more "at risk" subgroups, offered the vaccine free of charge. In addition, some Italian Regions have recently tried to make flu vaccination compulsory for all Healthcare Workers (HCWs). Since 2017, when the law on childhood vaccination in Italy was passed, compulsory vaccination has proved to be a successful strategy towards coverage increase.
Identifiants
pubmed: 32921733
doi: 10.23750/abm.v91i3.10549
pmc: PMC7716975
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2020031Références
Hum Vaccin Immunother. 2020 Aug 26;:1-8
pubmed: 32845739
Lancet Glob Health. 2020 Oct;8(10):e1264-e1272
pubmed: 32687792
Lancet Glob Health. 2020 Aug;8(8):e1003-e1017
pubmed: 32553130
Ann Ig. 2018 Jul-Aug;30(4 Supple 1):1-10
pubmed: 30062373
Hum Vaccin Immunother. 2017 Nov 2;13(11):2531-2537
pubmed: 29048980
J Prev Med Hyg. 2017 Jun;58(2):E141-E154
pubmed: 28900354
Vaccine. 2017 Mar 1;35(9):1209-1210
pubmed: 26657186
Lancet Public Health. 2020 Jun;5(6):e310
pubmed: 32339478
Acta Biomed. 2020 Jul 20;91(9-S):7-18
pubmed: 32701911
Lancet Glob Health. 2020 Jul;8(7):e901-e908
pubmed: 32405459
Eur J Public Health. 2019 Dec 1;29(6):1003-1004
pubmed: 31808818
Nature. 2018 Mar 1;555(7694):30
pubmed: 29493608
Euro Surveill. 2019 Apr;24(15):
pubmed: 30994104
Vaccine. 2016 Jun 8;34(27):3102-3108
pubmed: 27154392
Crit Rev Oncol Hematol. 2016 Jan;97:157-67
pubmed: 26346895
BMJ. 2015 Jan 14;350:h116
pubmed: 25589037
Infect Genet Evol. 2018 Oct;64:57-64
pubmed: 29909243
Acta Biomed. 2020 Apr 10;91(3-S):71-76
pubmed: 32275270
Vaccine. 2017 Jul 24;35(33):4057-4059
pubmed: 28651836
Expert Rev Vaccines. 2019 Nov;18(11):1201-1209
pubmed: 31674847
Acta Biomed. 2019 Sep 13;90(9-S):21-27
pubmed: 31517886